Physician profile
Subhash C Proothi
NPI 1376537621
$19,589.74
in general payments reported to CMS, 2019-2025
22 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,452 · 2020: $5,607 · 2021: $2,780 · 2022: $2,664 · 2023: $5,405 · 2024: $245 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,070 · Education: $567 · Food and Beverage: $283 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,070.00 |
| Education | $566.88 |
| Food and Beverage | $283.47 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,119.95 | 2020-2025 | |
| Pfizer INC. | $3,688.08 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,400.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $1,625.00 | 2022 | |
| Janssen Biotech, INC. | $1,549.90 | 2019-2023 | Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $1,277.73 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $848.19 | 2021-2023 | |
| Seagen INC. | $582.13 | 2020-2025 | |
| Daiichi Sankyo INC. | $556.66 | 2022 | |
| Beigene, Ltd. | $525.00 | 2021 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Astellas Pharma US INC | $199.77 | 2020 | |
| Genentech USA, INC. | $171.94 | 2019 | |
| Novocure INC. | $158.73 | 2024-2025 | Optune Lua (Novottf-200t) |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $124.74 | 2024 | Axios |
| Gilead Sciences, INC. | $11.92 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Proothi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.